Seqens CDMO North America, a pharmaceutical manufacturer of new chemical entities (NCEs), active pharmaceutical ingredients (APIs), and other specialty chemical products, has appointed Jean-Noel David as managing director for North America. He replaces Ed Price, co-founder and president of the business, who will continue to serve as a consultant.
 
David’s mission is to grow Seqens’ CDMO business in North America, which includes plans to add manufacturing capacity, equipment and staff. Based on his experience as vice president for business transformation at Patheon Biologics, where he led the integration of acquisitions, he will also continue to push integrating U.S. operations with capacity and resources available throughout Seqens’ 24 manufacturing sites and R&D centers around the world.
 
Based in Newburyport, David sees serving the needs of customers seeking new supply chain partnerships as a priority.
 
“Due to Covid-19, more customers are looking to develop alternatives to their current supply chain and are asking for our help. The combined capabilities of Seqens North America and Europe, where Seqens is very well-known, ideally positions us to help them in new ways,” David commented.
 
David’s global experience, having lived and worked on five continents and speaking four languages, will help current and prospective sponsors tap additional Seqens’ resources, equipment and expertise. He earned an MBA from the Goizueta Business School at Emory University, received a Master’s of Science from ENSTA Paris and a bachelor’s degree from the Pierre and Marie Curie University.